A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

被引：65
|
作者：
Cha, Yoon Jin [1 ]
Cho, Byoung Chul [2 ]
Kim, Hye Ryun [2 ]
Lee, Hye-Jeong [3 ]
Shim, Hyo Sup [1 ]
机构：
[1] Yonsei Univ, Severance Hosp, Dept Pathol, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Yonsei Canc Ctr, Dept Oncol, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Severance Hosp, Dept Radiol, Coll Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 05期
关键词：
Lung adenocarcinoma; Anaplastic lymphoma kinase; Crizotinib; Resistance; Small cell lung carcinoma;
D O I：
10.1016/j.jtho.2015.12.097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Histologic changes can be involved in resistance to anticancer drugs. Transformation to small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors has been reported in patients with EGFR-mutant lung adenocarcinoma. Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：E55 / E58
页数：7
相关论文
共 50 条
  • [31] Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
    Gandhi, Leena
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3737 - 3742
  • [32] Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
    Liang, N.
    Xing, P.
    Su, Y.
    Long, X.
    Gao, Y.
    Chen, P.
    Zhang, Z.
    Liu, J.
    Li, B.
    Zhang, T.
    Mao, X.
    Zhang, L.
    Liu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1073 - S1073
  • [33] Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming
    Borges, Gisely T.
    Vencio, Eneida F.
    Quek, Sue-Ing
    Chen, Adeline
    Salvanha, Diego M.
    Vencio, Ricardo Z. N.
    Nguyen, Holly M.
    Vessella, Robert L.
    Cavanaugh, Christopher
    Ware, Carol B.
    Troisch, Pamela
    Liu, Alvin Y.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (09) : 2040 - 2047
  • [34] Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
    Liang, N.
    Xing, P.
    Su, Y.
    Long, X.
    Gao, Y.
    Chen, P.
    Liu, H.
    Zhang, T.
    Li, B.
    Zhang, L.
    Mao, X.
    Zhang, Z.
    Liu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S483 - S483
  • [35] THE USE EXPERIENCE OF CRIZOTINIB (XALKORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER
    Noma, Daisuke
    Sakamoto, Kazuhiro
    Ando, Kohei
    Amano, Shinya G.
    Sudo, Shigeto
    Goto, Hideto
    Yamakawa, Yasushi
    Tsubakihara, Motofumi
    Tsuboi, Masahiro
    Masuda, Munetaka
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1320 - S1320
  • [36] ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?
    Audigier-Vaiette, Clarisse
    Girard, Nicolas
    Cortot, Alexis B.
    Mennecier, Bertrand
    Debieuvre, Didier
    Planchard, David
    Zalcman, Gerard
    Moro-Sibilot, Denis
    Cadranel, Jacques
    Barlesi, Fabrice
    BULLETIN DU CANCER, 2014, 101 (09) : 823 - 831
  • [37] A Case of a Pregnant Woman Diagnosed as Having ALK-rearranged Lung Adenocarcinoma
    Komura, Moegi
    Yagishita, Shigehiro
    Nakamura, Kota
    Arano, Naoko
    Takeshige, Tomohito
    Muraki, Keiko
    Nagashima, Osamu
    Izumi, Hiroshi
    Tomita, Shigeki
    Sasaki, Shinichi
    Takahashi, Kazuhisa
    IN VIVO, 2018, 32 (05): : 1205 - 1209
  • [38] Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
    Nagumo, Yoshiyuki
    Maejima, Aiko
    Toyoshima, Yuta
    Komiyama, Motokiyo
    Yonemori, Kan
    Yoshida, Akihiko
    Fujimoto, Hiroyuki
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2018, 48 : 1 - 4
  • [39] Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
    Pal, Sumanta K.
    Bergerot, Paulo
    Dizman, Nazli
    Bergerot, Cristiane
    Adashek, Jacob
    Madison, Russell
    Chung, Jon H.
    Ali, Siraj M.
    Jones, Jeremy O.
    Salgia, Ravi
    EUROPEAN UROLOGY, 2018, 74 (01) : 124 - 128
  • [40] Identification of resistance mutations to crizotinib through circulating tumor cell (CTC) analysis in ALK-rearranged non-small-cell lung cancer (NSCLC)
    Pailler, Emma
    Faugeroux, Vincent
    Oulhen, Marianne
    Forcato, Claudio
    Laporte, Melanie
    Lecluse, Yann
    Lacroix, Ludovic
    NgoCamus, Maud
    Nicotra, Claudio
    Remon, Jordi
    Mezquita, Laura
    Planchard, David
    Soria, Jean-Charles
    Manaresi, Nicolo
    Besse, Benjamin
    Farace, Francoise
    CANCER RESEARCH, 2018, 78 (13)
12345